The Five Truths Reshaping Indian Pharma

Indian pharma is a $55B market today. It will be $130B by 2030. But, most mid-tier companies in 2026, are still running by 2015 rules. I just dropped a new podcast episode breaking down the five structural truths that will separate the compounders from the also-rans in Indian pharma over the next decade. Here’s what we cover:1. Digitization is permanent and the real cost of delay isn’t technology spend, it’s data. Tata 1mg went from 19% to 31% e-pharmacy market share in 12 months. That gap compounds.2. The customer has changed — the patient, the physician and the institution, the family, the influencers are all transforming simultaneously. Most companies are managing one of the three.3. The macro isn’t a headwind, it is a restructuring. 954 NLEM formulations. 17,000 Jan Aushadhi stores. ₹2,000+ crore in generic sales in FY25 alone. This is policy architecture, not a cycle.4. Compounds, competitors, consumers — all shifting. Sun Pharma’s specialty business now out-earns its generics in the US. Zepto is delivering medicines in 10 minutes. The category boundaries pharma assumed as protective are all gone.5. The window to consolidate leadership is open — but not indefinitely.Three screening questions I walk through in the episode:→ Do you have pricing power that NLEM can’t reach?→ Do you own a data asset that compounds?→ Is your cost structure built for a price-regulated world?Would love to hear what you’d push back on. Listen in. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com